Bendamustine Is a Hybrid Antimetabolite and Alkylating Agent Offering New Therapeutic Options for the Treatment of Non-Hodgkin Lymphomas. Hematol Meeting Rep 2009, 2 (5). https://doi.org/10.4081/hmr.v2i5.749.